Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, Kiuchi T, Miyake Y, Tanaka K, Chiba T
Department of Transplantation Immunology, Faculty of Medicine, Kyoto University, Japan.
Transplantation. 1998 Feb 27;65(4):494-9. doi: 10.1097/00007890-199802270-00007.
In order to clarify the risk of hepatitis B virus (HBV) transmission from hepatitis B core antibody-positive (HBcAb(+)) donors and to evolve a new strategy to counter such a risk, we undertook a retrospective (1990-1995) and prospective (1995-1996) analysis of our experience with living related liver transplantation involving HBcAb(+) donors.
Between June 15, 1990, and June 30, 1995, HBcAb(+) individuals were not excluded as donor candidates at our institutions. For 171 liver transplants, 16 donors were HBcAb(+). Between July 1, 1995, and June 30, 1996, HBcAb(+) individuals were generally excluded as donor candidates; however, three recipients were given liver grafts from HBcAb(+) donors because other donor candidates presented even higher risks. In the latter period, recipients with transplants from HBcAb(+) donors underwent prophylactic passive immunization with hyperimmune hepatitis B immunoglobulin (HBIG). The serum of 10 HBcAb(+) donors was examined by nested polymerase chain reaction for the presence of HBV-DNA, but it was not detected in any of them. However, the same examination of the liver tissue of five such donors yielded positive results in all cases.
In the first 5-year period, out of 16 recipients with HBcAb(+) donors, 15 became hepatitis B surface antigen-positive after transplant. The three recipients with HBcAb(+) donors during the second 1-year period, who were treated by prophylactic passive immunization with HBIG, remained hepatitis B surface antigen-negative and negative for serum HBV-DNA after transplant.
HBV exists in the liver of healthy HBcAb(+) individuals, but not in the blood. Therefore, HBV is thought to be transmitted to recipients by liver grafts from the HBcAb(+) donors at a significantly high rate. The prevention of viral activation and clinical disease development by means of passive immunization with HBIG seems promising, although the follow-up period in our study may be too short for any definitive conclusions.
为了阐明乙肝核心抗体阳性(HBcAb(+))供体传播乙肝病毒(HBV)的风险,并制定应对该风险的新策略,我们对涉及HBcAb(+)供体的亲属活体肝移植经验进行了回顾性(1990 - 1995年)和前瞻性(1995 - 1996年)分析。
在1990年6月15日至1995年6月30日期间,我们机构未将HBcAb(+)个体排除在供体候选者之外。在171例肝移植中,有16例供体为HBcAb(+)。在1995年7月1日至1996年6月30日期间,HBcAb(+)个体一般被排除在供体候选者之外;然而,有3例受者接受了来自HBcAb(+)供体的肝脏移植,因为其他供体候选者存在更高的风险。在后一时期,接受来自HBcAb(+)供体移植的受者接受了高效价乙肝免疫球蛋白(HBIG)的预防性被动免疫。对10例HBcAb(+)供体的血清进行巢式聚合酶链反应检测HBV - DNA的存在情况,但在所有供体中均未检测到。然而,对5例此类供体的肝组织进行同样检测,所有病例结果均为阳性。
在第一个5年期间,16例接受HBcAb(+)供体移植的受者中,有15例在移植后乙肝表面抗原呈阳性。在第二个1年期间,3例接受HBcAb(+)供体移植且接受了HBIG预防性被动免疫治疗的受者,在移植后乙肝表面抗原仍为阴性,血清HBV - DNA也为阴性。
HBV存在于健康HBcAb(+)个体的肝脏中,但不存在于血液中。因此,HBV被认为通过来自HBcAb(+)供体的肝脏移植以相当高的比率传播给受者。尽管我们研究中的随访期可能太短,无法得出任何确定性结论,但通过HBIG被动免疫预防病毒激活和临床疾病发展似乎很有前景。